Clinicians routinely pair two routine lab values to determine kidney disease staging: the estimated glomerular filtration rate, which reflects how well your kidneys filter waste, and the albumin-to-creatinine ratio, which shows whether protein is leaking into your urine. The eGFR places you on a scale from G1 (≥90) down to G5 (<15 mL/min/1.73 m²), while the albuminuria result places you on a separate A1 to A3 scale. Those two axes together produce a combined risk category that drives referrals, medication choices, and follow-up timing.
The sections below decode each number, walk through a typical lab report, map the symptoms that tend to surface at each stage, and outline the questions worth bringing to your next nephrology visit.
What Kidney Disease Staging Actually Measures
Chronic kidney disease (CKD) is defined as a persistent loss of filtration or structural kidney damage lasting three months or more, not a single abnormal lab value. A creatinine of 1.3 mg/dL one morning does not make you a kidney patient; the same creatinine three months later, paired with a low eGFR and a urine albumin result above 30 mg/g, does. That durability requirement is what separates chronic disease from a brief reaction to dehydration, a new medication, or a short illness.
Two measurements, not one, define your stage. The first is the estimated glomerular filtration rate, a calculation telling your clinician how many milliliters of blood your kidneys filter per minute, normalized to a standard 1.73 m² body surface area. The second is albuminuria, the amount of the protein albumin leaking into urine, which signals damage to the glomerular membranes that normally hold large proteins back. Looking only at eGFR misses half the picture, which is why KDIGO and the National Kidney Foundation’s KDOQI recommendations now stage by combining both axes into a grid.
Where Creatinine Fits In
Serum creatinine is the waste product used to estimate filtration. Creatinine comes from normal muscle breakdown, the kidneys clear it steadily, and when filtration drops, creatinine accumulates in the blood. Elevated creatinine alone does not define a stage, but it is the raw input for the eGFR equation printed right next to it on your lab report.
The GFR Categories That Define Each of the Five Stages
The KDIGO staging system uses six G categories, G1 through G5, with G3 split into G3a and G3b because the clinical picture changes meaningfully across that band. The table below shows each stage and what the filtration range typically means for symptoms and care.
| Stage | eGFR (mL/min/1.73 m²) | What It Usually Means |
|---|---|---|
| G1 | 90 or higher | Kidney function is normal or high; damage may still exist if albuminuria or structural disease is present. |
| G2 | 60 to 89 | Mildly reduced filtration, often still without symptoms; albuminuria drives risk. |
| G3a | 45 to 59 | Mild to moderate decline; first symptoms may appear; cardiovascular risk climbs. |
| G3b | 30 to 44 | Moderate to severe decline; symptoms become more common and nephrology referral is standard. |
| G4 | 15 to 29 | Severely reduced; complications such as anemia, bone-mineral disorder, and metabolic acidosis set in. |
| G5 | Under 15 | Kidney failure; renal replacement therapy (dialysis or transplant) becomes the next decision. |
The G3 Split and Why It Matters
Stage 3a and 3b can look like an arbitrary line drawn in the 30s, but the jump in cardiovascular risk, fatigue, and referral urgency between the two halves is real. An eGFR of 50 carries a meaningfully different prognosis than 35, even though both technically sit in Stage 3. Guidelines split the band because medication decisions, the need for phosphorus and potassium monitoring, and the timing of vascular access planning all shift once filtration falls below 45.
The Three-Month Rule
An eGFR below 60 mL/min/1.73 m² that persists for three months or longer establishes the diagnosis of CKD, even when no other markers of damage are obvious on imaging or urine tests. That single line in the guideline is why repeat testing matters: a low eGFR from one blood draw is not a stage, while a low eGFR confirmed on a second draw, at least 90 days apart, is.
Two draws and a three-month gap sound arbitrary, but they exist to rule out a reversible dip before committing to a stage.
Why Albuminuria Matters as the Second Axis of Staging
The albumin-to-creatinine ratio (ACR) measures how much albumin appears in a spot urine sample relative to the creatinine in that same sample. Because creatinine concentration varies with hydration, dividing albumin by creatinine gives a more stable number than albumin alone, which is why most labs report ACR rather than just protein. A value under 30 mg/g is considered normal; between 30 and 300 signals moderately increased albuminuria; above 300 marks severely increased albuminuria and a much steeper risk curve.
The Three Albuminuria Categories
- A1, Normal to mildly increased: ACR under 30 mg/g, the standard goal for most patients with diabetes or hypertension.
- A2, Moderately increased: ACR between 30 and 300 mg/g, often the threshold at which a nephrologist tightens medication choices.
- A3, Severely increased: ACR above 300 mg/g, the highest risk band, where rapid decline and cardiovascular events become the central concern.
Same eGFR, Different Risk
An eGFR of 45 in two different patients can mask strikingly different downstream risks. The patient with an ACR of 15 mg/g lives in a low-risk corner of the KDIGO grid. The patient at 45 eGFR with an ACR of 450 mg/g sits in a high-risk corner and is far more likely to progress to kidney failure within a decade. Staging without albuminuria would lump those two together; the dual-axis grid separates them.
How Doctors Calculate eGFR and Read Your Lab Report
The number printed on your lab report as “eGFR” comes from the 2021 CKD-EPI creatinine equation, a race-free formula that replaced older MDRD calculations in most U.S. laboratories. The formula takes your serum creatinine, age, and sex, and produces an estimate of filtration standardized to a 1.73 m² body surface area. Some reports also include a cystatin C-based eGFR, which can be ordered when creatinine is unreliable because of extreme muscle mass, amputation, or chronic illness.
Decoding a Typical Lab Printout
- Creatinine: reported in mg/dL, with a reference range roughly 0.6 to 1.2 for adults; higher values mean less filtration.
- eGFR: the calculated stage indicator next to it; anything below 60 for three months triggers a CKD diagnosis.
- ACR: read alongside the eGFR to determine the A1, A2, or A3 category.
- Footnotes and flags: small letters such as “L” or asterisks tell the clinician whether the number falls outside the lab’s reference range.
Tip: ask for a printed or portal copy of every lab draw and bring both the most recent result and the one from three months earlier to your nephrology visit. Showing the trajectory in front of the clinician shortens the conversation and keeps attention on whether the line is flat, falling, or steep.
When Confirmatory Testing Comes Next
Before a stage is formally assigned, clinicians often order a repeat creatinine, a urine albumin screen, and sometimes a renal ultrasound to rule out obstruction, scarring, or a kidney that is small and shriveled from long-standing damage. A single low eGFR is rarely acted on alone, especially in someone who was dehydrated, had a recent illness, or started a new medication that affects kidney clearance.
Symptoms, Complications, and Treatment Focus at Each Stage
Early CKD is famously silent, which is why most people first learn about their diagnosis from a routine blood draw rather than a symptom. That absence of warning signs is one reason screening matters for anyone with diabetes, hypertension, a family history of kidney failure, or a history of repeated kidney stones.
The Early, Silent Stages (G1 and G2)
Filtration at or above 60 mL/min/1.73 m² is usually enough to keep blood pressure, fluid balance, and waste removal stable, so symptoms often show up only after albuminuria becomes heavy or eGFR begins to drift downward. Your practical focus at this point is controlling the upstream causes: blood pressure, blood sugar, weight, smoking, and any nephrotoxic exposures such as NSAIDs taken for chronic pain.
The Symptomatic Middle (G3a, G3b, and G4)
The first signs of decline tend to appear in G3a and intensify through G3b. Fatigue that does not match activity level, mild ankle swelling by evening, nighttime urination that interrupts sleep, foamy urine from protein leakage, and a creeping need to adjust blood pressure medications are all common. By G4 the picture grows more complicated: anemia from low erythropoietin, bone-mineral disorder from disturbed phosphorus and calcium handling, and metabolic acidosis from accumulated acid loads. This is the stage where planning for the future starts to matter, because G4 is often the window in which a transplant evaluation, a dialysis access discussion, or both get started.
Kidney Failure and Renal Replacement (G5)
Stage 5 means filtration under 15 mL/min/1.73 m² and the accumulation of waste, fluid, and electrolytes the body can no longer clear on its own. Renal replacement therapy becomes the next decision, which in practice means choosing among hemodialysis (in-center or home), peritoneal dialysis, and kidney transplantation. Each option carries different lifestyle implications: in-center hemodialysis runs three days a week on a fixed schedule, home dialysis offers more flexibility but demands training and a care partner, and transplant evaluation takes months and depends on donor availability.
With treatment options in hand, the next question is which guideline your nephrologist is actually following to set them in motion.
Evidence-Based Actions at Every Stage
- Stages G1 and G2: control blood pressure, optimize blood sugar if diabetic, reduce salt and ultra-processed foods, and avoid chronic NSAIDs.
- Stage G3a: add regular albuminuria monitoring, screen for cardiovascular risk factors, and review every medication for kidney safety.
- Stage G3b: tighten nephrology follow-up, discuss medications shown to slow progression, and begin advance-care conversations early.
- Stage G4: prepare for renal replacement by learning about dialysis modalities, starting transplant evaluation, and protecting vascular access sites.
- Stage G5: finalize the dialysis or transplant plan that fits your life, schedule the access procedure, and keep nutrition and emotional support strong.
Differences Between KDIGO and KDOQI, and How Staging Guides Care
The two main guideline bodies, KDIGO and NKF KDOQI, largely agree on the G1 through G5 framework. The big difference is that KDIGO overlays the albuminuria A1 to A3 grid on top of filtration categories, producing combined risk groups, while KDOQI historically focused on filtration stages and is increasingly aligned with the same dual-axis approach. American Society of Nephrology clinical practice now routinely follows KDIGO’s combined risk model because it predicts outcomes more accurately than eGFR alone.
How a Combined G and A Category Drives Care
A combined result of, say, G3a and A2 puts you in a moderate-risk group, while G3a with A3 lands you in a high-risk group even with identical filtration. That risk band then drives referral urgency, the choice of medications such as SGLT2 inhibitors or non-steroidal mineralocorticoid receptor antagonists, the frequency of monitoring, and how aggressively blood pressure and diabetes are managed.
Tip: when reviewing your labs, ask your clinician which combined G and A category you sit in and what the goal is for the next visit. A specific target like “get ACR under 30 within six months” turns the next appointment into a checkpoint instead of a repeat performance.
What to Bring to Your Next Appointment
Walking in prepared turns a routine visit into a working session. Bring the most recent creatinine, eGFR, and ACR results plus the same numbers from three to six months earlier so the trend is visible, a short symptom log covering energy, swelling, and urine changes, a complete medication list including over-the-counter drugs and supplements, and a written list of questions about stage progression, options for slowing decline, and preparation steps for advanced care if applicable. That single page of preparation usually changes the conversation more than any new test.
Staging is not just a label. It is the shared language between you, your primary clinician, and your nephrologist that turns lab numbers into a plan you can act on.
FAQ
What are the 5 stages of kidney disease?
The five stages are defined by eGFR: G1 (≥90), G2 (60–89), G3a (45–59), G3b (30–44), G4 (15–29), and G5 (<15 mL/min/1.73 m²). Stage 3 is split because risk and symptoms change meaningfully across that band.
How is kidney disease staged?
Staging combines the eGFR calculated from a blood creatinine test with the albumin-to-creatinine ratio from a urine sample. Together they place you in a G category and an A category, producing a combined risk group.
What eGFR number indicates stage 3 kidney disease?
An eGFR between 30 and 59 indicates Stage 3, split into 3a (45–59) and 3b (30–44). The split exists because cardiovascular risk and symptom burden rise noticeably once filtration falls below 45.
Can kidney disease be reversed if caught early?
Early CKD cannot usually be reversed, but its progression can often be slowed for years with blood pressure control, blood sugar management, and medications that protect kidney function, especially in Stages 1 through 3.
What tests determine kidney disease stage?
Serum creatinine (used to calculate eGFR), the urine albumin-to-creatinine ratio, and often a renal ultrasound to assess structure. Repeat testing at least three months apart confirms a chronic, not transient, change.
How fast does kidney disease progress through stages?
Progression varies widely. Some patients stay in Stage 3 for decades; others with heavy albuminuria or uncontrolled diabetes can move from G3 to G5 in a few years. Tracking the slope of eGFR over time is more useful than any single number.
